Sulfonylureas

A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position

Top

Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Diabetes Obes Metab. 2014;16:1041-1047.

Association between intensification of metformin treatment with insulin vs sulfonylureas and CV events and all-cause mortality among patients with diabetes

Top

Roumie CL, Greevy RA, Grijalva CG, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA. 2014;311(22):2288-2296.

Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus

Top

Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110:826-833. This meta-analysis from Patil and colleagues provides insights into the effects of DPP-4 inhibitors on cardiovascular (CV) events, and is the first adequately powered study that shows a class-wide effect for DPP-4 inhibitors in decreasing CV event risk over long-term treatment (≥24 weeks).

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin

Top

Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-483. A recent position statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) cites metformin as the optimal first-line drug for diabetes treatment. However, the statement acknowledges that limited data exist regarding treatments to be used beyond metformin.

Effects of intensive glucose lowering in type 2 diabetes

Top

The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study investigated the effects of intensive glucose-lowering therapy on CV event reduction among patients with type 2 diabetes and either risk factors for, or established, cardiovascular disease.

β-cell function preservation after 3.5 years of intensive diabetes therapy

Top

Harrison LB, Adams Huet B, Raskin P, Lingvay I. Beta cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012;35(7):1406-1412. To assess beta-cell function preservation after 3.5 years of intensive therapy with insulin plus metformin (INS group) versus triple oral therapy (TOT group) with metformin, glyburide, and pioglitazone.

Meta-analysis: DPP-4 Inhibitors for Type 2 Diabetes

Top

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Meta-analysis: DPP-4 Inhibitors for Type 2 Diabetes. BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369. Karagiannis and colleagues conducted a systematic review and meta-analysis of 27 studies to evaluate the efficacy of DPP-4 inhibitors for treatment of type 2 diabetes when compared with other antihyperglycemic therapies.

EUREXA: Exenatide vs Glimepiride for Prevention of Glycemic Deterioration Among Those with Type 2 Diabetes and Metformin Failure

Top

Exclusive! Expert commentary from Burton E. Sobel, MD, on the EUREXA trial. Gallwitz B, Guzman J, Dotta F, et al. EUREXA: Exenatide vs Glimepiride for Prevention of Glycemic Deterioration Among Those with Type 2 Diabetes and Metformin Failure. Lancet. 2012;379(9833):2270-2278. The European Exenatide (EUREXA) trial is an open-label, randomized, controlled trial comparing add-on exenatide with glimepiride for durability of glycemic control among subjects with type 2 diabetes that is inadequately controlled with metformin monotherapy.

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes

Top

Horowitz M, Flint A, Jones KL, et al. Effect of the once daily human GLP 1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012 Mar 23. Epub ahead of print. Liraglutide reduces bodyweight in patients with type 2 diabetes mellitus (T2DM). This study aimed to investigate the mechanisms underlying this effect.

Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort

Top

Best JD, Drury PL, Davis TM, Taskinen MR, Kesäniemi YA, Scott R, Pardy C, Voysey M, Keech AC on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study investigators. Glycemic control over 5 years in 4,900 people with type 2 diabetes real world diabetes therapy in a clinical trial cohort. Diabetes Care. 2012 Mar 19. Epub ahead of print. Glycemic control in type 2 diabetes generally worsens over time, requiring intensification of therapy. The Fenofibrate Intervention and Event Lowering in Diabetes trial provided the opportunity to observe glycemic control in a real-world setting.

1 2 3 4 5 6 7 Next